<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract" xml:lang="en"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Immunother Cancer</journal-id><journal-id journal-id-type="iso-abbrev">J Immunother Cancer</journal-id><journal-title-group><journal-title>Journal for Immunotherapy of Cancer</journal-title></journal-title-group><issn pub-type="epub">2051-1426</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">4646117</article-id><article-id pub-id-type="publisher-id">2051-1426-3-S2-P136</article-id><article-id pub-id-type="doi">10.1186/2051-1426-3-S2-P136</article-id><article-categories><subj-group subj-group-type="heading"><subject>Poster Presentation</subject></subj-group></article-categories><title-group><article-title>Comparative study of sequential intravesical chemotherapy using gemcitabine and mitomycin C with mitomycin C alone for non-muscle invasive bladder carcinoma- a randomized trial</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Jayant</surname><given-names>Kumar</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A2"><name><surname>Kumar</surname><given-names>Santosh</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A3"><name><surname>Singh</surname><given-names>Shrawan kumar</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A4"><name><surname>Agrawal</surname><given-names>Swati</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A5"><name><surname>Agrawal</surname><given-names>Rajendra</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib></contrib-group><aff id="I1"><label>1</label>SHMRC/PGIMER, Kota, India</aff><pub-date pub-type="collection"><year>2015</year></pub-date><pub-date pub-type="epub"><day>4</day><month>11</month><year>2015</year></pub-date><volume>3</volume><issue>Suppl 2</issue><supplement><named-content content-type="supplement-title">30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015)</named-content><named-content content-type="supplement-sponsor">Publication of this supplement was funded by SITC 2015.</named-content></supplement><fpage>P136</fpage><lpage>P136</lpage><permissions><copyright-statement>Copyright &#x000a9; 2015 Jayant et al.</copyright-statement><copyright-year>2015</copyright-year><copyright-holder>Jayant et al.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><self-uri xlink:href="http://www.immunotherapyofcancer.org/content/3/S2/P136"/><conference><conf-date>4-8 November 2015</conf-date><conf-name>30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015)</conf-name><conf-loc>National Harbor, MD, USA</conf-loc></conference></article-meta></front><body><sec><title>Introduction</title><p>This study was conducted to investigate the ablative efficacy and safety of sequential intravesical gemcitabine and mitomycin C with mitomycin C alone in refractory non-muscle invasive bladder cancer (NMIBC).</p></sec><sec><title>Methods</title><p>A total of 219 patients with refractory NMIBC were prospectively enrolled at tertiary academic center over period of Feb 2009-Jan 2012 &#x00026; followed for next 3 yrs. They were randomly assigned to either of treatment arms: Gentamycin &#x00026; mitomycin C (group A) or mitomycin C (group B). All patients underwent a 6-week induction regimen followed by a monthly maintenance regimen for one year if they responded to the induction course.</p></sec><sec><title>Results</title><p>In Group A 98 of 102 &#x00026; in group B 94 of 96 patients completed the therapy and were evaluated for response while 6 patient left the therapy in between. The therapy was well tolerated in the rest of patients. In group&#x02018;A&#x02019; i.e Gentamycin &#x00026; mitomycin C a total, 82 patients (83.67%) exhibited a complete response to intravesical therapy. In 12.2% (12) patients had biopsy proven recurrence (22&#x000b1;6.16 months). In group &#x02018;B&#x02019; (mitomycin C), 63 (65.60%) patients exhibited a complete response to intravesical therapy, 22 patients (22.9%) showed a partial response. During follow-up, 16 patients (25.3%) developed recurrence within this period. (14.5 +/- 8.26 months).</p></sec><sec><title>Conclusions</title><p>Chemoresection with sequential intravesical gemcitabine and mitomycin C administration may be a viable option for BCG refractory non-muscle invasive bladder cancer (NMIBC).</p><fig id="F1" position="float"><label>Figure 1</label><graphic xlink:href="2051-1426-3-S2-P136-1"/></fig><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Detail parameters of both groups.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Parameters</th><th align="left">Group A</th><th align="left">Group B</th><th align="left">P value</th></tr><tr><th align="left"/><th align="left">(MMC+Gemcitabine)</th><th align="left">(MMC)</th><th align="left"/></tr></thead><tbody><tr><td align="left">Total patients</td><td align="left">102</td><td align="left">96</td><td align="left">NS+</td></tr><tr><td align="left">Male</td><td align="left">81</td><td align="left">78</td><td align="left">NS+</td></tr><tr><td align="left">Female</td><td align="left">21</td><td align="left">19</td><td align="left">NS+</td></tr><tr><td align="left">Age</td><td align="left">65.7&#x000b1;9.8 yrs</td><td align="left">63.9&#x000b1;8.9 yrs</td><td align="left">NS+</td></tr><tr><td align="left">Mean Duration of follow up</td><td align="left">36 months</td><td align="left">36 months</td><td align="left"/></tr><tr><td align="left">Mean size of tumor &#x0003c;2cm</td><td align="left">63</td><td align="left">58</td><td align="left">NS+</td></tr><tr><td align="left">Mean sixe of tume &#x0003e;2 cm</td><td align="left">39</td><td align="left">38</td><td align="left">NS+</td></tr><tr><td align="left">Stage Ta</td><td align="left">60</td><td align="left">58</td><td align="left">NS+</td></tr><tr><td align="left">Stage T1</td><td align="left">42</td><td align="left">38</td><td align="left">NS+</td></tr><tr><td align="left">Grade 1</td><td align="left">19</td><td align="left">17</td><td align="left">NS+</td></tr><tr><td align="left">Grade 2</td><td align="left">63</td><td align="left">61</td><td align="left">NS+</td></tr><tr><td align="left">Grade 3</td><td align="left">20</td><td align="left">18</td><td align="left">NS+</td></tr><tr><td align="left">Previous treatment with BCG</td><td align="left">All</td><td align="left">All</td><td align="left"/></tr><tr><td align="left">Aim of complete response</td><td align="left">100%</td><td align="left">100%</td><td align="left"/></tr><tr><td align="left">Actual complete response</td><td align="left">83.67% (82)</td><td align="left">65.6% (63)</td><td align="left">0.001*</td></tr><tr><td align="left">Recurrence %</td><td align="left">12.2% (12)</td><td align="left">25.3% (16)</td><td align="left">0.001*</td></tr><tr><td align="left">Recurrence</td><td align="left">22&#x000b1;6.16 months</td><td align="left">14.5&#x000b1;8.26 months</td><td align="left">0.001*</td></tr><tr><td align="left">Recurrence range in months</td><td align="left">8-36 months</td><td align="left">4-14 months</td><td align="left"/></tr></tbody></table><table-wrap-foot><p>Values are presented as mean (+/- standard devitation)</p><p>Group A: Gemcitabine &#x00026; Mitomycin (MMC+Gentamycin)</p><p>Group B: Mitomycin C(MMS)</p><p>*Statistical significance was analyzed by student t-test</p><p>+Statistical significance was analyzed by the chi-square test.</p></table-wrap-foot></table-wrap><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Details of adverse effects of therapy in both groups.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Parameters</th><th align="left">Group A</th><th align="left">Group B</th><th align="left">P value</th></tr><tr><th align="left"/><th align="left">Gemcitabine + MMC</th><th align="left">Mitomycin C(MMC)</th><th align="left"/></tr></thead><tbody><tr><td align="left">Dysuria</td><td align="left">11.7% (12)</td><td align="left">7.2% (7)</td><td align="left">NS+</td></tr><tr><td align="left">Suprapubic pain</td><td align="left">11.7% (12)</td><td align="left">9.3% (9)</td><td align="left">NS+</td></tr><tr><td align="left">Hematuria</td><td align="left">3.9% (4)</td><td align="left">3.1% (3)</td><td align="left">NS+</td></tr><tr><td align="left">Chemical Cystitis</td><td align="left">7.8% (8)</td><td align="left">6.25% (6)</td><td align="left">NS+</td></tr><tr><td align="left">Local reaction</td><td align="left">6.8% (7)</td><td align="left">4.16% (4)</td><td align="left">NS+</td></tr><tr><td align="left">Skin reaction</td><td align="left">5.8% (6)</td><td align="left">4.16% (4)</td><td align="left">NS+</td></tr></tbody></table><table-wrap-foot><p>Group A: Gemcitabine &#x00026; Mitomycin (MMC+Gentamycin)</p><p>Group B: Mitomycin C(MMS)</p><p>*Statistical significance was analyzed by student t-test</p><p>+Statistical significance was analyzed by the chi-square test.</p></table-wrap-foot></table-wrap><fig id="F2" position="float"><label>Figure 2</label><caption><p>CONSORT diagram showing the participants through each stage of a randomized trial.</p></caption><graphic xlink:href="2051-1426-3-S2-P136-2"/></fig></sec></body></article>